All In Biotech

Drug Trial Radar · NCT04971109

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 467 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

467

Actual

Start

Mar 29, 2022

Primary completion

May 12, 2023

Study completion May 12, 2023

Sponsor

Lead sponsor
SIGA TechnologiesIndustry
Sponsor type
Industry
Collaborators
United States Department of Defense
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.

Conditions

  • Smallpox

Interventions

  • TPOXXDrug

    Study is based on Animal Regulatory Rule

  • TPOXX PlaceboOther

    Does not apply

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CminTime frame: 28 days
  2. CmaxTime frame: 28 days
  3. AUC(0-last) - Total Systemic TPOXX ExposureTime frame: 28 days
  4. Time To Maximum TPOXX ExposureTime frame: 28 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami, LLC

    Miami, Florida

  • Advanced Pharma

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • Meridian Clinical Research

    Omaha, Nebraska

  • Hassman Research Institute

    Berlin, New Jersey

  • High Point Clinical Trials Center

    High Point, North Carolina

  • Midwest Clinical Research Center

    Dayton, Ohio

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • PPD Phase I Clinic

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.